88IV - Public company info - Meilleure Health International Industry Group Limited

Input the stock code or the company name

Search

Financial Ratios

Meilleure Health International Industry Group Limited, 02327.HK - Company Profile
Chairman	Zhou Xuzhou
Share Issued (share)	4,272,000,000
Par Currency	Hong Kong Dollar
Par Value	0.01
Industry	Biotechnology
Corporate Profile	Business Summary: The Group was mainly involved in the following principal activities: 1.Trading business — Trading of healthcare products and construction materials 2.Agency service — Real estate and construction materials agency services 3.Property development — Development of residential properties 4.Property investment and leasing 5.Healthcare related business — Health management services Performance for the year: Revenue for the year ended 31 December 2019 was HK$234.8 million (2018: HK$230.5 million). The Group’s gross profit for the year ended 31 December 2019 was HK$71.8 million (2018: HK$90.2 million), representing a decrease of 20.4% compared to that for the year ended 31 December 2018. Gross profit margin for the year decreased to 30.6% from 39.1% for the year ended 31 December 2018. The Group recorded a loss attributable to owners of the parent of HK$20.2 million for the year ended 31 December 2019 as compared to a profit attributable to owners of the parent of HK$80.5 million for the year ended 31 December 2018. Business Review Trading Business The revenue derived from the trading business for the year ended 31 December 2019 was HK$145.1 million, representing an increase of 22.1% as compared to HK$118.8 million for the year ended 31 December 2018. The result for this segment changed from a profit of HK$16.2 million for the year ended 31 December 2018 to a loss of HK$13.4 million for the year ended 31 December 2019. This was mainly due to recognition of the Group’s share of impairment loss of intangible assets of Yunnan Hansu during the year ended 31 December 2019. Such impact was offset by an increase in customers’ demand for steel in the second half of 2019. Agency Service The revenue derived from the agency service for the year ended 31 December 2019 was HK$29.3 million, representing a decrease of 37.3% as compared to HK$46.7 million for the year ended 31 December 2018. The profit derived from this segment for the year ended 31 December 2019 was HK$13.6 million, representing a decrease of 66.0% as compared to HK$40.0 million for the year ended 31 December 2018. Such decreases were mainly due to a decrease in customers’ demand for construction materials agency services in 2019. Property Investment and Leasing The revenue from the property investment and leasing business for the year ended 31 December 2018 and 2019 were HK$18.7 million. The profit derived from this segment for the year ended 31 December 2019 was HK$45.5 million, representing a decrease of 41.3% as compared to HK$77.5 million for the year ended 31 December 2018. The decreases were mainly due to a decrease in fair value gains on investment properties. Healthcare Related Business The revenue derived from the healthcare related business for the year ended 31 December 2019 was HK$41.6 million, representing a decrease of 10.0% as compared to HK$46.2 million for the year ended 31 December 2018. The result for this segment changed from a profit of HK$3.0 million for the year ended 31 December 2018 to a loss of HK$4.4 million for the year ended 31 December 2019. This was mainly due to a decrease in customers’ demand for health management service in the second half of 2019 resulted from the social movement in Hong Kong. Prospects: Looking forward into 2020, the Epidemic casted uncertainties in the global economic outlook. However, the traditional business of the Group will continue to provide a stable cash flow, and the outlook of the two future-proof core segments look positive. Meanwhile, the Group has current assets of HK$889.8 million, including cash and cash equivalents of HK$156.2 million and redeemable financial assets at fair value through profit or loss of HK285.7 million respectively. These both create competitive advantage for the Company, and provide a solid development foundation in this economic climate that is filled with uncertainties. The Group has a certain extent of influence domestically and internationally. The group focus on product R&D, innovation and integrated marketing, and brand building. By utilizing the advantage of the group's internationalised operation, the group can establish a healthcare enterprise group that focuses on health management, the health applications of cannabinoid and cell pharmaceutical business. The group will expand the group's investment in capital and human resources, and adhere to the “one core and two wings” strategy which focuses on high-end health management business driven by the health applications of cannabinoid and cell. The group will also launch pioneering and innovative products, and create marketing channels and brands with entry barriers. At the same time, the group will continue the group's efforts in discovering business partners that are with favorable traits, outstanding, and sincere, to strengthen the group's core competiveness in the above-mentioned business.

Information from the financial statements of listed companies

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2024

Suntek Computer Systems Limited.

All rights reserved